Cell Source, Inc. logo
CLCS

Cell Source, Inc.

MaveScore 33 Low model confidence
Last Price US$0.95 As of Jul 10, 2026
Market Cap US$42.8m Company size context
7D Performance 2.15% Past 7 days
1Y Performance 227.59% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Mar 31, 2025

467 days old

Market price date

Jul 10, 2026

1 day old

Coverage

14/16

2 missing model inputs

Data quality

Review

Partial or delayed snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 33 Low confidence

Stored data quality

Freshness and coverage checks

14/16 Partial or delayed snapshot

Quality

12/35 Weak

Blends latest model rank with profitability and dilution ranks.

Financial Strength

4/25 Weak

Rewards durable profitability, margins, and positive free cash flow.

Valuation Support

5/15 Weak

Favors positive earnings, positive cash flow, and lower multiples.

Momentum

12/15 Strong

Highlights research candidates with supportive 3-month and 6-month price regimes.

Shareholder Alignment

0/10 Weak

Rewards less dilutive share behavior and enough size for liquid research coverage.

Positive model output

  • Highlights research candidates with supportive 3-month and 6-month price regimes.

Research risks to review

  • Blends latest model rank with profitability and dilution ranks.
  • Rewards durable profitability, margins, and positive free cash flow.
  • Favors positive earnings, positive cash flow, and lower multiples.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin.

Dashboard Funda..tals Prediction Screener Map

Cell Source, Inc. Overview

Industry: Biotechnology

Sector: Healthcare

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune response Read More

Cell Source, Inc. is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

Cell Source, Inc.

Score

Reported Results

What the company reported, with filing details kept small.

Filed May 14, 2026

Quarterly result summary

Latest company-filed earnings material is available for source review.

What changed

  • Review the SEC source filing for the full reported results and management commentary.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

SEC filing Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Recent News



Earnings Per Share

Score 3.00/5
Cell Source, Inc. boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Return on Equity

Score 1.77/5
Cell Source, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Cell Source,... CLCS US$42.8m
Zoetis Inc ZTS US$31.4b
IQVIA Holdin... IQV US$34.6b
Agilent Tech... A US$36.9b

Net Margin

Score 2.21/5
Cell Source, Inc. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Cell Source,... CLCS US$42.8m
Zoetis Inc ZTS US$31.4b
IQVIA Holdin... IQV US$34.6b
Agilent Tech... A US$36.9b

Share Buyback

In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Leverage

Score 3.00/5
Cell Source, Inc. attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Cell Source,... CLCS US$42.8m
Zoetis Inc ZTS US$31.4b
IQVIA Holdin... IQV US$34.6b
Agilent Tech... A US$36.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

SEC financial statements are temporarily unavailable.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Cell Source, Inc. logo

Cell Source, Inc.

US$0.95

US$42.8m

2.15%

227.59%